2018-02-27T10:48:41-07:00 2017-06-30 990 2016-07-01 730580274 Oklahoma Medical Research Foundation OKLA 4052717421 825 NE 13th Street Oklahoma City OK 73104 Tim Hassen Chief Financial Officer 4052717421 2018-02-27 157.142.200.2 2016 2021-01-29 14:40:06Z Tim Hassen VP and CFO 825 NE 13th Street Oklahoma City OK 73104 79122620 0 X www.omrf.org X 1946 OK OMRF is dedicated to developing a better understanding of and more effective treatments for human disease. 71 71 502 0 0 0 55448766 58846030 9728825 9992552 2658578 4487212 4536479 5469397 72372648 78795191 0 0 0 0 34522756 35108542 0 0 1995352 38620467 40004795 73143223 75113337 -770575 3681854 379327594 390204230 63023022 55594045 316304572 334610185 OMRF is dedicated to developing a better understanding of and more effective treatments for human disease. 0 0 23316776 0 15135578 Arthritis & Clinical Immunology/Clinical Operations - Recognized by the National Institutes of Health as one only 10 Autoimmunity Centers of Excellence in the country, researchers in this program focus on diseases in which the body mistakenly turns the weapons of the immune system against itself. By blending laboratory research with patient studies, program leader Dr. Judith James and her colleagues have created a model for how physicians and scientists can work together to create better outcomes for people suffering from conditions such as lupus, rheumatoid arthritis and multiple sclerosis. This partnership between researchers and clinicians spurred the publication of 70 new research studies this past year, including dozens on the molecular mechanisms of lupus and one that identified 24 new genes associated with the disease. The discovery of these new genes brings the total number of known lupus genes to 101; OMRF researchers have played a role in identifying or confirming 65 of those. 5648864 0 7774716 Cardiovascular Biology Research Program - Scientists in this program concentrate their research on the blood-how it flows, how it clots and how blood vessels grow. Work in this program is fundamental to understanding and treating a wide variety of diseases, and in 2017 research led down many different paths. Important studies cast new light on heart failure and kidney disease. OMRF cardiovascular biologists also made significant progress toward more effective treatments for victims of traumatic injuries like gunshot wounds and motor vehicle accidents. Finally, in July, the global pharmaceutical company GSK selected a group of OMRF cardiovascular biologists to participate in its highly selective Discovery Partnerships with Academia program. Dedicated to bringing together the insight and creativity of leading academic scientists with GSK's drug discovery expertise, the partnership will focus on creating novel therapies to prevent organ damage and death caused by conditions such as acute pancreatitis, lung injury and trauma. "We are very excited to initiate this target-to-medicine collaboration," says Carolyn Buser-Doepner of GSK. "[It represents] a unique approach to finding ways to prevent organ failure and death in acute injury." 2567550 0 3045853 Aging and Metabolism Research Program - With work that shares the theme of trying to improve people's healthspans-the length of time they enjoy active, productive lives-scientists in this program won a grant in 2017 to study how proteins responsible for Alzheimer's disease can also accelerate age-related loss of muscle mass and function. In addition, they made discoveries about how physical and dietary factors associated with obesity contribute to the development of arthritis, metabolism's effect on the ability of the heart to repair itself after a heart attack, and ways in which diabetes impacts cardiac metabolism. The year ended with the successful recruitment of Dr. Michael Beckstead, an electrophysiologist who has made a series of new discoveries on the role that a brain peptide that may play in Parkinson's disease. 37227465 0 12103988 Other Program Services 37227465 0 12103988 68760655 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 1 0 0 0 1 0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 126 0 1 502 1 0 0 0 0 1 1 1 1 0 0 0 1 1 0 X 71 71 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 OK X X X Tim Hassen 4052717421 825 NE 13th Street Oklahoma City OK 73104 Allen Greg S Board Member 1 0 X 0 0 0 Anoatubby Bill Board member 1 0 X 0 0 0 Bell Sharon Board Member 1 0 X 0 0 0 Benbrook Bruce Board Member 1 0 X 0 0 0 Benham Lance Board Member 1 0 X 0 0 0 Boghetich Jil Board Member 1 0 X 0 0 0 Braught Barbara Board Member 1 0 X 0 0 0 Brown Randy Board Member 1 0 X 0 0 0 Burgess Ellen Board Member 1 0 X 0 0 0 Carolina Mike Board Member 1 0 X 0 0 0 Carroll Michael Board Member 1 0 X 0 0 0 Cason Len Board Member 1 0 X 0 0 0 Cawley Michael Board Member 1 0 X 0 0 0 Champlin Hiram Board Member 1 0 X 0 0 0 Collins Mark Board Member 1 0 X 0 0 0 Drake Ramsey Board Member 1 0 X 0 0 0 Duncan Walt Board Member 1 0 X 0 0 0 Eagan Claire Board Member 1 0 X 0 0 0 Edwards Carl Board Member 1 0 X 0 0 0 Evans Pat Board Member 1 0 X 0 0 0 Everest Christy Board Member 1 0 X 0 0 0 Felton Ann Board Member 1 0 X 0 0 0 Fergeson Ken Board Member 1 0 X 0 0 0 Fischer Malinda Board Member 1 0 X 0 0 0 Funke Mark Board Member 1 0 X 0 0 0 Gamble Gerald Board Member 1 0 X 0 0 0 Griffin John Board Member 1 0 X 0 0 0 Groendyke Virginia Board Member 1 0 X 0 0 0 Haglund Jacqui Board Member 1 0 X 0 0 0 Hall Brooks Board Member 1 0 X 0 0 0 Hargis Burns Board Member 1 0 X 0 0 0 Hatfield Judy Board Member 1 0 X 0 0 0 Hawley Bill Board Member 1 0 X 0 0 0 Henry Kim Board Member 1 0 X 0 0 0 Henry Robert Board Member 1 0 X 0 0 0 Hogan Randy Board Member 1 0 X 0 0 0 Holmes Jerome Board Member 1 0 X 0 0 0 Hudson Cliff Board Member 1 0 X 0 0 0 Jameson Brett Board Member 1 0 X 0 0 0 Johnstone Bill Board Member 1 0 X 0 0 0 Kelly Michael Board Member 1 0 X 0 0 0 Kern Terence Board Member 1 0 X 0 0 0 Kerr Lou Board Member 1 0 X 0 0 0 Levy Harrison Board Member 1 0 X 0 0 0 Little Dan Board Member 1 0 X 0 0 0 Loughridge Bill Board Member 1 0 X 0 0 0 Mahaney Mindy Board Member 1 0 X 0 0 0 McCarty Jack Board Member 1 0 X 0 0 0 Morris Jim Board Member 1 0 X 0 0 0 Nichols Larry Board Member 1 0 X 0 0 0 Parry Richard Board Member 1 0 X 0 0 0 Patten Rebecca Board Member 1 0 X 0 0 0 Payne Bond Board Member 1 0 X 0 0 0 Pierson Gary Board Member 1 0 X 0 0 0 Pitman Don Board Member 1 0 X 0 0 0 Rainbolt David Board Member 1 0 X 0 0 0 Replogle Dee Board Member 1 0 X 0 0 0 Rooney Pat Board Member 1 0 X 0 0 0 Ross Bob Board Member 1 0 X 0 0 0 Samis Mike Board Member 1 0 X 0 0 0 Saxon John Board Member 1 0 X 0 0 0 Schulte Paul Board Member 1 0 X 0 0 0 Stough Phyllis Board Member 1 0 X 0 0 0 Swimmer Ross Board Member 1 0 X 0 0 0 Switzer Becky Board Member 1 0 X 0 0 0 Taylor Steven Board Member 1 0 X 0 0 0 Thorpe Betsy Board Member 1 0 X 0 0 0 Walton Greg Board Member 1 0 X 0 0 0 Williams Jr G Rainey Board Member 1 0 X 0 0 0 Wymer Deane Board Member 1 0 X 0 0 0 Yauk Sarah Board Member 1 0 X 0 0 0 Prescott Stephen President and CEO 50 0 X 1021076 0 249865 Paul Kincade VP of Research & Member, Immunobiology and Cancer 50 0 X 147166 0 10636 Morgan Chip Executive VP & Chief Operating Officer 50 0 X 237060 0 37838 Cohen Adam Sr VP & General Counsel 50 0 X 231146 0 42732 Voss Penny VP of Development 50 0 X 205085 0 59890 Nair Manu VP of Technology Transfer 50 0 X 197596 0 37061 Hassen Tim VP and CFO 50 0 X 226113 0 49556 Day Lisa VP of Business and Government Affairs 50 0 X 120448 0 27122 Courtney Stevens VP of Human Resources 50 0 X 134786 0 30514 James Judith Program Chair, Arthritis and Clinical Immunology 50 0 X 385016 0 102294 McEver Rodger Program Chair, Cardiovascular Biology 50 0 X 264365 0 43388 Pardo Gabriel Associate Member, Arthritis and Clinical Immunology 50 0 X 334324 0 45616 Jones David Program Chair, Functional and Chemical Genomics 50 0 X 306905 0 49514 Gaffney Patrick Member, Arthritis and Clinical Immunology 50 0 X 273509 0 59400 Sivils Kathy Member, Arthiritis and Clinical Immunology 50 0 X 233515 0 44798 Nath Swapan Member, Arthritis and Clinical Immunology 50 0 X 246250 0 42844 Reyna Tania Clinical Assistant Member, Arthritis and Clinical Immunology 50 0 X 224353 0 23847 4788713 0 956915 56 0 1 0 Infusion Management LLC 11233 Shadow Creek Pkwy Pearland TX 77584 Medical Billing Services 7583588 Aramark 24863 Network Pl Chicago IL 606731248 HouseKeeping Services 524711 Parker Highlander 1120 S Capital of Texas Hwy Bldg One Ste 200 Austin TX 78746 Legal 104929 3 125322 0 454081 0 38416136 19850491 191082 58846030 Clinic Revenue 621399 9992552 9992552 0 0 0 0 0 0 9992552 4160638 4160638 0 0 68281 68281 0 0 2848852 2848852 0 0 382390 0 0 0 382390 0 382390 382390 0 0 191997 393725 191082 136347 915 257378 258293 258293 0 0 0 454081 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Cafe Income 722100 278379 278379 0 0 Laboratory Income 541380 1959776 1959776 0 0 0 0 0 0 2238155 78795191 19949161 0 0 3709267 2536530 967652 205085 0 23304405 21564015 772440 967950 8094870 7195575 542308 356987 172874 120101 52773 0 109250 75900 33350 0 586035 0 586035 0 1041697 1041697 0 0 444246 229839 52926 161481 891980 713271 111333 67376 3157135 2466451 690227 457 618562 544435 52252 21875 201913 192832 8834 247 1018229 997299 20930 0 7749116 7375056 374060 0 338442 235127 103315 0 Lab supplies 5565198 5565198 0 0 Trainee costs 891748 891748 0 0 Inhouse 815898 774872 26901 14125 Subconracts 15049235 15049235 0 0 1353237 1191474 -38006 199769 75113337 68760655 4357330 1995352 5100 4800 27129840 16040601 7414994 5599323 2572360 4537322 0 0 0 0 192000 292000 6968 14159 381912 326363 228007832 123855046 108749101 104152786 102596301 116921148 2169004 2137348 0 0 128110014 140178380 379327594 390204230 8380117 7935365 0 0 0 0 48783096 40355000 0 0 0 0 0 0 0 0 5859809 7303680 63023022 55594045 X 105600945 106534776 32525207 40977643 178178420 187097766 316304572 334610185 379327594 390204230 X 3681854 9455286 0 0 0 5168473 X 0 1 X 1 1 1 X 51804565 55978368 51927440 55448766 58846030 274005169 0 0 0 0 0 0 0 0 0 0 0 0 51804565 55978368 51927440 55448766 58846030 274005169 45644085 228361084 6515711 7714644 7176342 7195057 9956609 38558363 0 0 0 0 0 0 0 0 0 0 0 0 312563532 9992552 0.73061 0.74270 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 586035 0 0 586035 0 Schedule C, Part II-B, Line 1 The Foundation's lobbying activities entail monitoring proposed legislation and educating legislators and their staffs about the Foundation, medical research and the impact of proposed legislation on medical research and the Foundation. 82018035 246125 13280976 0 4000000 0 91545136 86604791 389217 -1175973 0 3800000 0 82018035 86302560 1057014 2745217 0 3500000 0 86604791 76260090 390308 12952162 0 3300000 0 86302560 66735078 3205030 9519982 0 3200000 0 76260090 0.0725 0.6005 0.327 1 0 3944520 0 3944520 180638795 0 90325553 90313242 0 0 0 0 43240450 0 33529493 9710957 184067 0 0 184067 104152786 Funds Held in Trust by Others 131697471 Wills and Bequests 4661889 Cash Surrender Value of Life Insurance 2817455 Debt Issue Costs 287278 Deposits 405364 Accrued Interest Receivable 87200 Assets Held for Sale 221616 Minerals 107 140178380 0 Split Interest Agreements & Other Liabilities 1249851 Postretirement Benefits & Deferred Compensation 6053829 7303680 X 93418950 9455286 0 0 5168473 14623759 78795191 0 0 0 78795191 75113337 0 0 0 0 0 75113337 0 0 0 75113337 Schedule D, Part V, Line 4 The Foundation's endowment consists of individual funds established to provide the Foundation with funding in perpetuity. Schedule D, Part X, Line 2 Management has reviewed the Foundation's tax positions and concluded that there are no uncertain tax positions that require accrual in the financial statements or disclosure in the footnotes to be in compliance with authoritative literature. Generally, the Foundation is no longer subject to income tax examination by federal, state or local tax authorities for years prior to 2014. Schedule D, Part XI, Line 2d Includes change in fair value of funds held in trust by others as well as pension related changes other than net periodic pension costs. In FY 2017, this amount also included the early extinguishment of debt of $3,880,051 from the defeased 2008 bond. East Asia and the Pacific 0 8 Speaking at Seminars or Conferences 27277 Europe (including Iceland and Greenland) 0 16 Speaking at Seminars or Conferences 62115 Middle East and North Africa 0 1 Speaking at Seminars or Conferences 2260 South America 0 1 Speaking at Seminars or Conferences 1475 South Asia 0 3 Speaking at Seminars or Conferences 11774 Sub-Saharan Africa 0 3 Program Services Research 143007 Europe (including Iceland and Greenland) 0 1 Program Services Education 783 North America (including Canada and Mexico, but not the United States) 0 0 Investments 256613 Central America and the Caribbean 0 0 Investments 3002560 0 33 3507864 0 0 0 1 1 0 241 Event 584996 0 584996 0 9499 12125 24943 54427 29921 0 0 584996 0 584996 0 9499 12125 24943 54427 29921 130915 454081 X 1 1 X X X X X X 0 1 0 0 0 0 0 1 0 Prescott Stephen President and CEO 769374 0 206820 0 44882 0 236045 0 11347 0 1268468 0 0 0 Paul Kincade VP of Research & Member, Immunobiology and Cancer 123586 0 0 0 23580 0 0 0 10636 0 157802 0 0 0 Morgan Chip Executive VP & Chief Operating Officer 209032 0 150 0 27878 0 25801 0 11347 0 274208 0 0 0 Cohen Adam Sr VP & General Counsel 192956 0 0 0 38190 0 31901 0 10141 0 273188 0 0 0 Voss Penny VP of Development 184908 0 275 0 19902 0 42026 0 17174 0 264285 0 0 0 Nair Manu VP of Technology Transfer 196216 0 0 0 1380 0 22586 0 15135 0 235317 0 0 0 Hassen Tim VP and CFO 218253 0 150 0 7710 0 30192 0 18674 0 274979 0 0 0 Day Lisa VP of Business and Government Affairs 116063 0 0 0 4385 0 9517 0 17669 0 147634 0 0 0 Courtney Stevens VP of Human Resources 132230 0 0 0 2556 0 13883 0 16632 0 165301 0 0 0 James Judith Program Chair, Arthritis and Clinical Immunology 348581 0 0 0 36436 0 92429 0 10526 0 487972 0 0 0 McEver Rodger Program Chair, Cardiovascular Biology 219894 0 0 0 44471 0 31351 0 11347 0 307063 0 0 0 Pardo Gabriel Associate Member, Arthritis and Clinical Immunology 333502 0 0 0 822 0 31941 0 12985 0 379250 0 0 0 Jones David Program Chair, Functional and Chemical Genomics 305903 0 0 0 1002 0 31651 0 17174 0 355730 0 0 0 Gaffney Patrick Member, Arthritis and Clinical Immunology 259257 0 0 0 14252 0 41536 0 17174 0 332219 0 0 0 Sivils Kathy Member, Arthiritis and Clinical Immunology 232603 0 0 0 912 0 27625 0 17834 0 278974 0 0 0 Nath Swapan Member, Arthritis and Clinical Immunology 211813 0 10125 0 24312 0 25671 0 17834 0 289755 0 0 0 Reyna Tania Clinical Assistant Member, Arthritis and Clinical Immunology 223663 0 0 0 690 0 23847 0 12923 0 261123 0 0 0 Schedule J, Part I, Line 1a First class travel is allowed for the CEO to allow him to accomplish work related tasks while traveling. Schedule J, Part I, Line 3 Compensation for the CEO is determined by leadership of the board of directors based on comparability data from widely accepted peer benchmarking surveys that are segmented by region and size of entity. Schedule J, Part I, Line 4 The Board of the Foundation periodically uses nonqualified retirement plans as a retention tool. Schedule J, Part I, Line 7 The CEO receives an annual bonus that is determined by leadership of the board of directors based on performance. The bonus is considered as a portion of total compensation and is subject to the review process previously described. A Oklahoma Industries Authority 736194355 679103YC9 2008-08-14 42955000 Revenue Bonds (OMRF Project) Series 2008 1 0 0 B Oklahoma Industries Authority 736194355 000000000 2010-05-26 12185000 Revenue Bonds (OMRF Project) Series 2010 0 0 0 C Oklahoma Industries Authority 736194355 000000000 2016-07-13 29535000 Revenue Bonds (OMRF Project) Series 2016 0 0 0 A 8345000 35610000 43955000 0 0 39047489 141976 0 0 30540129 0 9418857 2011 0 0 1 1 B 0 0 12185000 1218339 0 0 138825 0 0 0 10963136 0 2001 1 0 1 1 C 1365000 0 29535000 2953564 0 26315325 266175 0 0 0 0 0 2011 0 1 1 1 A 0 0 0 1 1 0 0 0 0 0 1 B 0 0 0 1 1 0 0 0 0 0 1 C 0 0 0 1 1 0 0 0 0 0 1 A 0 0 0 1 0 0 0 1 1 B 1 0 0 0 0 1 C 0 1 0 0 0 0 0 0 1 A 1 B 1 C 1 Schedule K, Part IV, Line 2c-08/14/2008 42,955,000 Oklahoma Industries Authority No rebate was due according to the rebate calculated November 21, 2013 for the rebate period beginning May 26, 2010 through June 30, 2013. Accele Biopharm Common Directors 400000 Equity Investment 0 Bank of Oklahoma Common Directors 299616 Investment and mineral asset management 0 Accele Venture Partners Common Directors 42611 Equity Investment 0 X 27 191082 FMV 0 0 1 1 Schedule M, Part I, Line 32b A third party is used to sell gifts of stocks or bonds received from donors. Usually the donor transfers the stocks directly from their brokerage account into OMRF's third party account. Occasionally, OMRF receives stock certificates and those are sent directly to the third party to process. Form 990, Part VI, Section A, Line 1a The Foundation's Board of Directors has delegated all of its powers to the Foundation's Executive Committee, except as follows: establish the overall policies and direction of the Foundation, appoint the members of the Executive Committee, elect and remove the Chair of the Board of Directors, amend the Bylaws and the Certificate of Incorporation of the Foundation, and appoint special committees to the Board of Directors. The Board of Directors may at any time amend or revoke this delegation of powers. Form 990, Part VI, Section A, Line 2 The Foundation currently has 78 directors, many of whom are business leaders and members of prominent families in the State of Oklahoma. The Foundation believes there are multiple business relationships between and among board members and families of Board members, but the Foundation review of signed conflict of interest disclosures from all board members and of the Foundation's ledger accounts indicated there are no such relationships that would impair the fiduciary duties of any director to the Foundation. Form 990, Part VI, Section B, Line 11b A summary of the Form 990 is presented for review to the Executive Committee. Subsequent to that review, the Form 990 with all supplemental schedules is made available to all members of the board of directors for review and comment prior to filing. Form 990, Part VI, Section B, Line 12c Each director, officer and key employee is annually provided with a copy of the Foundation's conflict of interest policy. Each of these individuals is annually provided with a questionnaire regarding potential conflicts and required to disclose any potential conflict that he or she might have. In addition, each of these individuals must annually sign a statement affirming that he or she has; received a copy of the conflicts of interest policy, read and understood the policy and agrees to comply with the policy. Once the Foundation has collected annual disclosure statements from all directors, officer and key employees, the Foundation's Governance Committee reviews such information to identify situations in which a potential conflict exists and is material. If a potential material conflict is identified, the committee analyzes whether the contemplated transaction may be authorized as just, fair, and reasonable to the Foundation. The Governance Committee then makes a recommendation to the Foundations' Executive Committee regarding the management of all potential conflicts it has identified. The final decision as to the approval and , where applicable, management of all such potential conflicts rests in the sole discretion of the Executive Committee, which makes such decisions based upon the welfare of the Foundation and the advancement of its purpose. The recommendations of the Governance Committee and decisions of the Executive Committee are documented in the respective minutes of these Committees' regular meetings. Form 990, Part VI, Section B, Line 15 Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Section C, Line 19 The Foundation's governing documents, conflicts of interest policy, and financial statements are provided upon request and are publicly available on the Foundation's website. Form 990, Part XI, Line 9 Includes change in fair value of funds held in trust by others as well as pension related changes other than net periodic pension costs. In FY 2017, this amount also included the early extinguishment of debt of $3,880,051 from the defeased 2008 bond.